Amy C. Peterson
CIK 1682735 · EVP Prod Dev & Med Aff & CMO · last filed 2025-05-16
Amy C. Peterson is an EVP Prod Dev & Med Aff & CMO who has filed 23 SEC Form 4 insider transactions across 3 companies since 2016. The most recent filing, for EXEL, was dated May 16, 2025. Across all open-market trades the lifetime net is −$12.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $28.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$28.77M
3
23
-$12.08M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| EXEL | EVP Prod Dev & Med Aff & CMO | 538,169 | $53.13 | $28.59M | -$3.31M | 6 | 2025-05-16 |
| CTMX | EVP, Chief Development Officer | 58,433 | $3.01 | $175.9K | -$19.0K | 9 | 2023-03-20 |
| BeOne Medicines Ltd. (BGNE) Delisted | CMO, Immuno-oncology | 2,776 | $184.71 | $512.8K | -$8.76M | 8 | 2018-12-19 |
Recent Filings
23 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-05-16 | EXEL | Mixed | −41,079 | -$2.81M | EDGAR |
| 2025-03-31 | EXEL | Grant (A) | +159,383 | $0 | EDGAR |
| 2025-02-28 | EXEL | Grant (A) | +52,192 | $0 | EDGAR |
| 2024-11-19 | EXEL | Tax (F) | −27,224 | -$954.2K | EDGAR |
| 2024-02-27 | EXEL | Grant (A) | +82,121 | $0 | EDGAR |
| 2023-08-25 | EXEL | Grant (A) | +240,000 | $0 | EDGAR |
| 2023-03-20 | CTMX | Sell (S) | −4,257 | -$8.4K | EDGAR |
| 2022-07-21 | CTMX | Mixed | +12,537 | -$10.6K | EDGAR |
| 2022-02-04 | CTMX | Grant (A) | +40,000 | $0 | EDGAR |
| 2021-10-26 | CTMX | Grant (A) | — | $0 | EDGAR |